Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Next Previous
Search
Trial Profile

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Vincristine (Primary)
  • Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Dec 2024 Planned End Date changed from 31 Oct 2024 to 30 Jun 2027.
  • 12 Dec 2024 Planned primary completion date changed from 31 Oct 2024 to 30 Jun 2027.
  • 18 Dec 2023 Planned End Date changed from 1 Oct 2024 to 31 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top